Analyst Price Targets — AARD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 5:41 am | Brian Abrahams | RBC Capital | $6.00 | $12.49 | StreetInsider | RBC Capital Downgrades Aardvark Therapeutics Inc (AARD) to Sector Perform |
| January 12, 2026 9:47 am | Chris Raymond | Raymond James | $47.00 | $14.27 | StreetInsider | Raymond James Reiterates Strong Buy Rating on Aardvark Therapeutics Inc (AARD) |
| December 23, 2025 11:23 am | Leland Gershell | Oppenheimer | $35.00 | $14.55 | TheFly | Aardvark Therapeutics initiated with an Outperform at Oppenheimer |
| November 14, 2025 9:30 am | Brian Abrahams | RBC Capital | $18.00 | $10.86 | StreetInsider | Aardvark Therapeutics Inc (AARD) PT Lowered to $18 at RBC Capital |
| September 29, 2025 8:43 am | — | Stifel Nicolaus | $24.00 | $13.23 | TheFly | Aardvark Therapeutics initiated with a Buy at Stifel |
| March 10, 2025 8:53 am | — | Morgan Stanley | $29.00 | $9.98 | TheFly | Aardvark Therapeutics initiated with an Overweight at Morgan Stanley |
Latest News for AARD
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective (“HERO”) trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome…
SAN FRANCISCO, April 10, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome…
SAN FRANCISCO, April 09, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective (“HERO”) trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome…
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AARD.
U.S. House Trading
No House trades found for AARD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.